The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study

NCT ID: NCT05434104

Last Updated: 2022-10-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 114 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-31
• Study Completion Date: 2024-06-30

Brief Summary

Three-quarters of women have bacterial vaginosis (BV) or vaginal thrush/candida yeast infection at least once during their lifetime. Symptoms can include abnormal vaginal discharge, soreness, itching and an unpleasant smell. BV during pregnancy can make the baby come too early. In the UK over a million women suffer recurrent vaginal infections. These can affect their sexual relationships and quality of life, and may need repeated courses of treatment. But some women prefer not to keep taking antibiotics which can have side effects and encourage the growth of resistant superbugs.

Lactoferrin is a prebiotic protein derived from cow's milk. Women also have naturally occurring lactoferrin in their vagina where it helps to prevent infections and encourage the growth of healthy bacteria. Recent research suggests lactoferrin may be an effective treatment for BV and thrush, but this needs to be confirmed.

Aim To see if it is feasible to conduct a future trial to prove whether lactoferrin vaginal pessaries are an acceptable, effective and cost-effective alternative to antibiotic tablets for women with BV or thrush.

Methods The investigators will recruit a total of 57 women with BV and 57 with thrush from two sexual health clinics and a general practice. Women will be asked to provide self-taken vaginal samples with a cotton bud, and to complete a confidential sexual-health questionnaire. Then the women will be divided into two groups. One group will be given lactoferrin vaginal pessaries to use every night for 3-weeks. The other group will be given antibiotic/antifungal tablets. All women will be asked to provide repeat vaginal samples at home and text us about any symptoms to see if the treatment works, if the infection comes back and if they would like antibiotics. After 12-weeks all women will be invited back for a final check-up.

Outcome measures:

• Acceptability and use of vaginal lactoferrin - from questionnaires, and interviews with 15-20 women
• Recruitment and follow-up rates
• Cost of lactoferrin treatment
• The percentage of women who report their symptoms have resolved after a week
• How quickly infections clear or recur - from analysis of samples

Patient benefit:

If this study leads to a trial showing vaginal lactoferrin is an acceptable and effective alternative to antibiotics, this could help relieve symptoms, prevent antimicrobial resistance and save NHS costs.

Detailed Description

Research Question: Is it feasible to conduct a future trial to investigate if Lactoferrin is an acceptable alternative to oral antibiotics/antifungals for women with bacterial vaginosis or thrush? Background Over 200,000 women are affected by bacterial vaginosis (BV) or vaginal candida/thrush each year in England. A million women suffer recurrent infections which many find distressing. The infections may also be associated with HIV infection and adverse pregnancy outcomes. Although BV and candida can be treated with oral antibiotics/antifungals, these can have side effects and encourage the development of antimicrobial resistance, a major global health problem.

Lactoferrin is a naturally occurring prebiotic protein present in the vagina where it helps to prevent infections and normalise the vaginal microbiome. It has been used to treat refractory BV and may also be effective against candida, but more evidence is needed.

Objective To see if it is feasible to conduct a future, definitive trial in women with BV or candida to investigate if vaginal lactoferrin pessaries are as effective as oral antibiotics in resolving symptoms, preventing recurrent infection and producing a healthy lactobacilli-dominated vaginal microbiome.

Design: open label randomised feasibility study over 12 weeks with qualitative, economic and microbiological evaluations.

Setting: a sexual health clinic and a general practice

Population 114 women with genitourinary symptoms and BV (n=57) or candida (n=57) confirmed on vaginal Gram stain. After completing questionnaires and providing self-taken vaginal samples women will be randomly allocated 2:1 into intervention or control groups. All women will be followed up with repeat samples and text/online questionnaires after 1,2,3,4 and 12 weeks.

Intervention 38 women with BV and 38 women with candida will be given vaginal 300mg lactoferrin pessaries to insert nightly for 21 nights

Comparator 19 women with BV will be given metronidazole 400mg twice daily for 5-days, and 19 women with candida will be given a fluconazole 150mg capsule.

Outcomes

• Acceptability of vaginal lactoferrin - from questionnaires, and interviews
• Adherence to treatment (from participants' weekly count of remaining pessaries/tablets)
• Recruitment rate and willingness of women to be randomised
• Follow-up rate
• Acceptability of study procedures such as providing vaginal samples and responding to texts about symptoms.
• Adverse events
• Estimate of the cost of lactoferrin and the feasibility of obtaining data on healthcare use
• Percentage of participants who complete twice weekly symptom questionnaires and provide self-taken vaginal samples at home which are suitable for microbiological analyses. These findings will inform the design of a future definitive trial.

Masking

This is an open label trial and there will be no blinding to treatment allocation of the participants or researchers. However, the analysis of samples (Gram stain and microbiome analysis) will be done blind to treatment allocation [1].

Sample size calculations and analysis

We will recruit 114 women in order to achieve a final sample of 90 followed-up women at 12-weeks (30 with BV given lactoferrin, 30 with candida given lactoferrin, and 30 controls (15 with BV, 15 candida) given oral antibiotics/antifungals. This allows for 24 women (21%) either lost to follow up (12%), recruited in general practice but not BV/thrush on Gram stain (4%) or given antibiotics for an STI (3%) an unrelated reason (2%, eg dental abscess) as antibiotics may affect both symptoms and the vaginal microbiome. Sixty intervention women and 30 controls is consistent with numbers recommended by Teare et al for feasibility studies and will provide an acceptable level of precision around the study's key feasibility outcomes [32].

For example, a recruitment rate of 50% (114/228) will have a 95% confidence interval of 43.5% to 56.5%; and a follow-up rate of 80% (91 /114) will have a 95% confidence interval of 72.5% to 87.2%.

Each week the sexual health specialist investigator sees an average of six eligible women in his recurrent vaginitis clinic and the general practitioner investigator sees one or two in general practice. PPI work and our previous trials suggest ≥50% of eligible women will agree to participate [26, 27]. If we recruit an average of 3 women a week (two in clinic, one in GP) we should complete recruitment of 114 women within 38 weeks. We will allow 12 months.

Analysis of quantitative study outcomes will be descriptive. Numbers and percentages will be presented, along with 95% confidence intervals. Weekly pessary/tablet counts will be presented as mean (SD) or median (IQR) as appropriate. Numbers of adverse events and number of women with adverse events will be summarised. The flow of participants through the study will be presented in a CONSORT diagram.

Timetable (months)

1-2 set-up 3-14 recruit 114 women and randomise 2:1 to lactoferrin/standard treatment 6-19 12-week follow-up in clinic 11-20 qualitative evaluation 13-20 statistical/cost/microbiome analyses 18-23 reports/dissemination

Impact/Dissemination

Study findings will be published in high impact journals and widely publicised. If progression criteria are met, (lactoferrin is acceptable to ≥70% of women, recruitment rate≥50%, follow-up ≥70%,) this could lead to a definitive trial which confirms that treating BV/candida with lactoferrin is an acceptable, effective, safe and cost-effective alternative to antibiotics. This could benefit women by reducing their use of antibiotics, preventing recurrent infections and decreasing the spread of antimicrobial resistance.

Conditions

Bacterial Vaginosis; Candida Vaginal

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: SINGLE

Study Groups

Lactoferrin intervention group

Women will be given bovine lactoferrin 300mg vaginal pessaries to insert every evening for the first 21 days of the study \[25\].

Group Type: EXPERIMENTAL

Vaginal lactoferrin

Intervention Type: OTHER

Lactoferrin vaginal pessaries to insert nightly for seven nights

Usual care control - standard oral antibiotics/antifungals

Control women with BV will be given oral metronidazole 400mg twice daily for five days (and routine advice about avoiding alcohol). Control women with candida will be given a fluconazole 150mg capsule to take orally the same day.

Group Type: ACTIVE_COMPARATOR

Usual care

Intervention Type: DRUG

Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole

Interventions

Vaginal lactoferrin

Lactoferrin vaginal pessaries to insert nightly for seven nights

Intervention Type: OTHER

Usual care

Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole

Intervention Type: DRUG

Other Intervention Names

Difesan vaginal pessaries; Oral metronidazole or fluconazole

Eligibility Criteria

Inclusion Criteria

• Aged 16-49 years

• Having periods (apart from women with a Mirena IUCD or polycystic ovary syndrome)
• Ability to consent
• Clinical diagnosis of BV or thrush confirmed on Gram stain
• Willing to be randomised to vaginal lactoferrin pessaries or oral antibiotics/antifungals
• Agrees to provide vaginal samples at home and post/deliver them back to the research team.
• Agrees to avoid douching during the study (as this can flush out lactobacilli needed for a healthy microbiome).

Exclusion Criteria

• Pregnant or breast feeding
• Currently has chlamydia, gonorrhoea or trichomonas (as treatment for these would affect the results).
• Known allergy to metronidazole or azoles
• Post-menopausal (because of diagnostic confusion between atrophic vaginitis and bacterial vaginosis)

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

King's College London

OTHER

Sponsor Role: collaborator

Statens Serum Institut

OTHER

Sponsor Role: collaborator

St George's, University of London

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pippa Oakeshott, MD

Role: PRINCIPAL_INVESTIGATOR

St George's, University of London

Locations

St Thomas' NHS Trust

London, , United Kingdom

St George's, University of London

London, , United Kingdom

Countries

United Kingdom

Central Contacts

Pippa Oakeshott, MD

Role: CONTACT

oakeshot@sgul.ac.uk

020 8725 0153

Fiona Reid, MSc

Role: CONTACT

fiona.reid@kcl.ac.uk

Facility Contacts

Phillip Hay, FRCP

Role: primary

phillip.Hay@gstt.nhs.uk

Other Identifiers

2021.0268

Identifier Type: -

Identifier Source: org_study_id